Breaking Canadian GLP-1 news
GLP-1 News
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Novo Nordisk Ozempic Savings Card Targets Uninsured Canadians
Novo Nordisk Canada launches a savings card for Ozempic aligning brand pricing with generics for uninsured Canadians, excluding Quebec, via Rexall pharmacies.
Novo Nordisk Guides 5-13% Revenue Drop as Canada Generics Bite
Novo Nordisk forecasts a 5-13% revenue decline in 2026 as Canadian generic semaglutide reaches pharmacies and the company rolls out a savings card outside Quebec.
Doustdar Calls Wegovy Pill a 'Must-Win' as Canada Generics Land
Novo Nordisk CEO Mike Doustdar frames the oral Wegovy launch as a must-win 2026 battle as Canadian generic semaglutide from Dr. Reddy's and Apotex ships.
Health Canada Backlog Tops 500 Files as Semaglutide Queue Sits at 7
The CGPA says over 500 generic submissions sit at Health Canada with 100+ backlogged, while seven generic semaglutide files still await decisions.
Novo Nordisk's Oral Wegovy Approved in U.S. as 2026 Fight Begins
Novo Nordisk secured U.S. approval for an oral Wegovy pill in December 2025, setting up a 2026 competitive battle with Eli Lilly's orforglipron.
Plan Sponsors Brace for Canada's 65% Semaglutide Price Trigger
Canadian benefits plans face a 65% list-price cut once a third generic semaglutide launches, with Sandoz now targeting Q3 2026 and Aspen going Canada-first.
Sandoz Estimates $200-$400 Generic Tirzepatide as Canada Warns on Fakes
Sandoz estimates its proposed generic tirzepatide at $200-$400 monthly as Health Canada renews warnings about unauthorized GLP-1 products sold outside licensed pharmacies.
Sandoz Files U.S. Generic Tirzepatide Bids as Lilly Raises Canada Prices
Sandoz's U.S. FDA generic tirzepatide filings land as Eli Lilly raises Mounjaro KwikPen prices in Canada under Trump administration pressure.
Health Canada Registry: Aspen-Semaglutide and Sevmia Approved, Neither Marketed
Health Canada's Drug Product Database lists Aspen-Semaglutide and Sevmia as Approved with no market date as of July 28, 2026. Why neither can be bought yet.
Novo Nordisk Let Canadian Ozempic Patent Extension Lapse: I-MAK
Novo Nordisk could have extended its Canadian Ozempic patent until 2028 but did not renew it, patent expert Tahir Amin of I-MAK told the BBC.
Health Canada Registry: Six Generic Semaglutide Files Pending
Health Canada's public submissions registry shows six generic semaglutide applications still under review after the June 29, 2026 Sevmia authorization.
TrumpRx US GLP-1 Deal: Limited Spillover for Canadian Prices
US TrumpRx program starts GLP-1 prices at US$350 dropping to US$245, but Canadian prices are already lower and generic semaglutide is reshaping the market.
Vimy Pharma Eyes Edmonton-Made Generic Semaglutide Launch
Toronto-based Vimy Pharma plans to file generic semaglutide with Health Canada, with production slated for an Edmonton facility employing about 30 people.
Apotex CEO Says US Launch of Generic Semaglutide Not in 2026
Apotex CEO Martin Arès told the BBC the company's generic semaglutide will not reach the US market in 2026 despite tentative FDA approval.
Sandoz Files US Generic Tirzepatide Applications; Canada Watches
Sandoz files two US generic tirzepatide applications with the FDA, estimating $200-$400 monthly pricing, as Canadian tirzepatide patents differ from US 2036 protection.
Health Canada Approves Sevmia (Apotex): Canada’s First Generic Wegovy
Health Canada approved Sevmia (Apotex) on June 29, 2026 — the first generic version of Wegovy and the first generic semaglutide cleared for weight management in Canada. Pricing has not been published yet.
Pharmacy-Level Generic Semaglutide Switch Mechanics Detailed
Endor Health details how Canadian pharmacies will substitute generic semaglutide at refill, with pCPA tiers setting public-plan prices at 85% down to 35% of brand.
Sandoz Cites Brazil Priority Review as Canada Wait Stretches On
Sandoz Canada points to Brazil's proactive prioritization of generic semaglutide submissions as the Canadian regulator continues to send back questions a year after filing.
Health Canada Review Cites 7.1M GLP-1 Prescriptions in 2023
Health Canada's Summary Safety Review discloses 7.1 million GLP-1 receptor agonist prescriptions dispensed by Canadian retail pharmacies in 2023.
Federal Budget Skips Health Canada Generic Backlog Fix: CGPA
Canada's federal budget omitted new Health Canada resources to clear a generic drug backlog, drawing criticism from CGPA's Jim Keon as semaglutide files queue.
Alberta Blue Cross: GLP-1 Plan Spend Won't Fall Despite Generic
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to fall despite a mid-2026 semaglutide generic, citing expanding uses and growing demand.
Novo Nordisk Details SOUL Trial Behind Rybelsus MACE Approval
Novo Nordisk Canada president Vince Lamanna detailed the SOUL trial of 9,650 patients behind Health Canada's MACE indication expansion for Rybelsus tablets.
Seven Generic Semaglutide Files Remain Under Health Canada Review
Health Canada is reviewing seven additional generic semaglutide submissions after Dr. Reddy's and Apotex authorizations, with more decisions expected in coming weeks.
Novo Nordisk Aligns Brand Ozempic Price With Generics in Canada
Novo Nordisk cuts brand-name Ozempic pricing for uninsured Canadians via its Savings Card, aligning costs with newly arrived generics from Apotex and Dr. Reddy's.
Eli Lilly Raises Mounjaro Prices in Canada Amid Trump Pressure
Eli Lilly raised Mounjaro list prices in Canada and Britain after Trump administration pressure, with Kwikpen wholesale prices now ranging $387 to $773.
Health Canada Safety Review: No GLP-1 Suicide Link in T2D Patients
Health Canada's Summary Safety Review found no evidence linking GLP-1 receptor agonists to suicide or self-harm in type 2 diabetes patients; obesity data inconclusive.
Apotex, Dr Reddy's Map Divergent Global Paths for Generic Semaglutide
Apotex CEO Martin Arès says the company is exploring US access routes while Dr Reddy's targets 80+ countries excluding US, UK and Europe.
TrumpRx Starts at US$350, Phases to US$245 as Canada Goes Generic
TrumpRx will sell GLP-1s starting at US$350, dropping to US$245 over two years, while Canada has approved two generic semaglutides, CBC and BMJ report.
Dr. Reddy's Generic Semaglutide Cleared NOD, NON Before Approval
Health Canada's Regulatory Decision Summary reveals Dr. Reddy's generic semaglutide cleared a Notice of Deficiency and Notice of Non-Compliance before April 28 approval.
Novo Nordisk Rebrands: Plosbrio, Poviztra Approved Dec 22, 2025
Health Canada approved two Novo Nordisk rebranded semaglutide products, Plosbrio and Poviztra, on December 22, 2025, as a defensive move against generics.
BBC Profiles Ottawa Patient Paying C$350-C$500 Monthly for Wegovy
BBC profiles Ottawa retiree Elizabeth Doran, 69, who paid C$350-C$500 monthly out of pocket for Wegovy and took substitute teaching shifts to afford it.
BBC: US Patients Eye Canadian Generic Semaglutide as Prices Diverge
BBC reports Americans may look north for generic semaglutide as Canadian patients access generics priced at less than a third of brand cost.
Selectpath Urges Plan Sponsors to Mandate Generic Substitution
Selectpath advisor warns Canadian plan sponsors that lower generic semaglutide prices may not cut total spend without mandatory substitution and tighter prior authorization.
Dr. Reddy's CEO Israeli Frames Canada Launch as Access Mission
Dr. Reddy's CEO Erez Israeli says the company remains dedicated to expanding GLP-1 access in Canada after becoming first to win generic semaglutide approval.
Alberta Blue Cross 2026 Pipeline: GLP-1 'Second Wave' Coming
Alberta Blue Cross's 2026 drug pipeline report flags a second wave of GLP-1 innovation, with MASH and sleep apnea indications keeping plan spend high.
Novo Nordisk: More Than 1 Million Canadians Take Semaglutide
Novo Nordisk says more than a million Canadians take a semaglutide drug, as CGPA reports 500+ generic submissions under Health Canada review with 100+ backlogged.
Health Canada Notice: Seven More Generic Semaglutide Files in Queue
After Apotex became Canada's second generic semaglutide approval on May 1, seven additional generic semaglutide submissions remain under review at Health Canada.
Rexall, Shoppers Expect Generic Semaglutide Shipments This Week
Rexall expects a generic semaglutide shipment by week's end and Shoppers Drug Mart says inventory is arriving at distribution centres and select stores.
Novo Nordisk Savings Card Routes Ozempic Discount Through Rexall
Novo Nordisk Canada's reduced Ozempic price for uninsured patients launches via a Savings Card applied automatically at Novo Nordisk Care Rx by Rexall, excluding Quebec.
Health Canada Hit 180-Day Generic Target 84% of Time in FY25
Health Canada met its 180-day generic review target 84% of the time in fiscal 2024-25 as 500+ submissions sit under review, including seven semaglutide files.
Novo Nordisk Cites 9,650-Patient SOUL Trial Behind Rybelsus Nod
Novo Nordisk's Rybelsus MACE indication in Canada is backed by the 9,650-patient SOUL trial, with President Vince Lamanna calling it an important milestone.
CDA Benchmarks Mounjaro to Ozempic's $228 List Price in Canada
Canada's Drug Agency suggests public plans pay no more for 5 mg Mounjaro than the $228 list price of 1 mg Ozempic, with 25-49% discounts at higher doses.
Obesity Canada Cites $27.6B Untreated Cost in Coverage Pivot
Obesity Canada's Sockalingam ties the $27.6B 2023 untreated-obesity cost and sub-20% private-plan coverage to Canada's G7-first generic semaglutide approval.
Saskatchewan Blue Cross: Generic Semaglutide Doesn't Change Plan Rules
Saskatchewan Blue Cross says coverage rules for semaglutide are not changing after Health Canada's G7-first generic approval, though out-of-pocket costs may fall.
Apotex 2 mg and 4 mg Pens Set to Hit Alberta Shelves 'Any Day'
Apotex told CBC its 2 mg and 4 mg pre-filled generic semaglutide pens will reach Alberta pharmacies 'any day', with stock orders starting this week.
Alberta Pharmacies Begin Ordering Generic Semaglutide This Week
Calgary pharmacist Wessam Sakr was notified he could start ordering generic semaglutide this week, with Apotex pens expected on Alberta shelves any day.
Walk-In Maps Patent Timeline Behind Canada's G7-First Generic
Walk-In Clinic details the 2020 patent lapse, January 2026 data exclusivity end, and March 2026 formulation patent expiry that opened Canada's generic semaglutide path.
CDA Mounjaro Math: Lilly's $300 Floor Meets a 25-49% Discount Ask
Canada's Drug Agency wants 25-49% off higher-dose Mounjaro list prices, even after Eli Lilly's December cut set 2.5 and 5 mg at $300 for four weeks.
BMJ: Canada Is Only the Second Country to Clear Generic Semaglutide
BMJ reports Canada is only the second country in the world to approve a generic semaglutide, with two products cleared and seven more under Health Canada review.
Health Canada Details DIN Checks, CBSA Role in GLP-1 Advisory
Health Canada's January 21 advisory tells buyers to verify GLP-1 drugs via eight-digit DIN and Drug Product Database, and flags CBSA cooperation on shipments.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada